Literature DB >> 18571706

Inhibition of the development of morphine tolerance by a potent dual mu-delta-opioid antagonist, H-Dmt-Tic-Lys-NH-CH2-Ph.

Yunden Jinsmaa1, Ewa D Marczak, Gianfranco Balboni, Severo Salvadori, Lawrence H Lazarus.   

Abstract

Three analogues of the dual mu-/delta-antagonist, H-Dmt-Tic-R-NH-CH2-Ph (R = 1, Lys-Z; 2, Lys-Ac; 3, Lys) were examined in vivo: 1 and 2 exhibited weak bioactivity, while 3 injected intracerebroventricularly was a potent dual antagonist for morphine- and deltorphin C-induced antinociception comparable to naltrindole (delta-antagonist), but 93% as effective as naloxone (nonspecific opioid receptor antagonist) and 4% as active as CTOP, a mu antagonist. Subcutaneous or oral administration of 3 antagonized morphine-induced antinociception indicating passage across epithelial and blood-brain barriers. Mice pretreated with 3 before morphine did not develop morphine tolerance indicative of a potential clinical role to inhibit development of drug tolerance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18571706      PMCID: PMC2597683          DOI: 10.1016/j.pbb.2008.05.008

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  37 in total

1.  Emergence of functional delta-opioid receptors induced by long-term treatment with morphine.

Authors:  Junyi Ma; Yong Zhang; Alex E Kalyuzhny; Zhizhong Z Pan
Journal:  Mol Pharmacol       Date:  2006-01-06       Impact factor: 4.436

2.  Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers.

Authors:  Raphael Rozenfeld; Lakshmi A Devi
Journal:  FASEB J       Date:  2007-03-23       Impact factor: 5.191

3.  Differentiation of opioid receptor preference by [Dmt1]endomorphin-2-mediated antinociception in the mouse.

Authors:  Yunden Jinsmaa; Yoshio Fujita; Kimitaka Shiotani; Anna Miyazaki; Tingyou Li; Yuko Tsuda; Yoshio Okada; Akihiro Ambo; Yusuke Sasaki; Sharon D Bryant; Lawrence H Lazarus
Journal:  Eur J Pharmacol       Date:  2005-01-22       Impact factor: 4.432

4.  Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia.

Authors:  I Sora; N Takahashi; M Funada; H Ujike; R S Revay; D M Donovan; L L Miner; G R Uhl
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

5.  Differential effects of naltrindole on morphine-induced tolerance and physical dependence in rats.

Authors:  M J Hepburn; P J Little; J Gingras; C M Kuhn
Journal:  J Pharmacol Exp Ther       Date:  1997-06       Impact factor: 4.030

Review 6.  Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving.

Authors:  Christian A Heidbreder; Jim J Hagan
Journal:  Curr Opin Pharmacol       Date:  2005-02       Impact factor: 5.547

7.  Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.

Authors:  Tingyou Li; Yoshio Fujita; Kimitaka Shiotani; Anna Miyazaki; Yuko Tsuda; Akihiro Ambo; Yusuke Sasaki; Yunden Jinsmaa; Ewa Marczak; Sharon D Bryant; Severo Salvadori; Lawrence H Lazarus; Yoshio Okada
Journal:  J Med Chem       Date:  2005-12-15       Impact factor: 7.446

8.  The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats.

Authors:  P W Schiller; M E Fundytus; L Merovitz; G Weltrowska; T M Nguyen; C Lemieux; N N Chung; T J Coderre
Journal:  J Med Chem       Date:  1999-09-09       Impact factor: 7.446

9.  The effect of cumulative dosing on the analgesic potency of morphine in mice.

Authors:  A Duttaroy; R Kirtman; F Farrell; M Phillips; J Philippe; T Monderson; B C Yoburn
Journal:  Pharmacol Biochem Behav       Date:  1997-09       Impact factor: 3.533

10.  Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord.

Authors:  L He; N M Lee
Journal:  J Pharmacol Exp Ther       Date:  1998-06       Impact factor: 4.030

View more
  2 in total

1.  Opioid Peptides: Potential for Drug Development.

Authors:  Jane V Aldrich; Jay P McLaughlin
Journal:  Drug Discov Today Technol       Date:  2012

2.  Orally administered H-Dmt-Tic-Lys-NH-CH2-Ph (MZ-2), a potent mu/delta-opioid receptor antagonist, regulates obese-related factors in mice.

Authors:  Ewa D Marczak; Yunden Jinsmaa; Page H Myers; Terry Blankenship; Ralph Wilson; Gianfranco Balboni; Severo Salvadori; Lawrence H Lazarus
Journal:  Eur J Pharmacol       Date:  2009-07-01       Impact factor: 4.432

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.